In a report released today, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $72.00. The company’s shares closed yesterday at $66.99.
Biegelsen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Abbott Labs, and Boston Scientific. According to TipRanks, Biegelsen has an average return of 12.3% and a 61.47% success rate on recommended stocks.
Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $68.64, implying a 2.46% upside from current levels. In a report released on February 27, Piper Sandler also maintained a Buy rating on the stock with a $72.00 price target.
See the top stocks recommended by analysts >>
Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.73 billion and a net profit of $481 million. In comparison, last year the company earned a revenue of $3.24 billion and had a net profit of $125 million
Based on the recent corporate insider activity of 114 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year. Earlier this month, Edward Ludwig, a Director at BSX sold 7,000.00 shares for a total of $455,210.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific (BSX) Company Description:
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
Read More on BSX:
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Boston Scientific price target raised to $70 from $60 at Barclays
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Boston Scientific price target raised to $63 from $55 at Deutsche Bank
- Boston Scientific price target raised to $73 from $70 at Truist
